Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: With numerous liquid biopsy tests now available its timely to consider their clinical utility and economics. Should CTCs and other bio-markers also be an integral part of any liquid biopsy? What about ‘blood-tests’ for early cancer detection? Should therapy selection be more intelligent & efficacious using predictive computational analysis? Is there a way to use these technologies to optimize the use of prohibitively expensive drugs?
Session Chair Profile
In 2012, as an Entrepreneur in Residence at a leading Silicon Valley Venture Firm, Artiman Ventures, Atul Sharan co-founded CellMax Life, applying semiconductor industry principles to a proprietary Circulating Tumor Cell (CTC) bio-mimetic CMx platform to develop affordable, clinically proven blood-tests for Early Cancer Detection and Treatment. He was motivated to start CellMax as two members of his family have been diagnosed with cancer – one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul is a veteran of the high-tech industry with experience as an engineer, serial entrepreneur, CEO and angel investor. He specializes in identifying unmet market needs and matching them with early stage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times: AutoESL (acquired by Xilinx); ClearShape Technologies (acquired by Cadence), Numerical Technologies (Nasdaq IPO; acquired by Synopsys); Ambit Design (acquired by Cadence). Atul holds a BS in Engineering from IIT-India; MS in Engineering from UH, Texas and an MBA from UC-Berkeley.
Presentation Title and Company Description
Liquid Biopsy Showcase: CTC For Affordable Accessible Early Cancer Detection
CellMax Life has developed the proprietary CTC platform CMxTM, to enable Early Cancer Detection. CMx tests are routine blood-draw based, globally affordable, with high sensitivity & specificity demonstrated in >1000 clinical samples. Commercially available in Asia and collaborating for our US Early Access program.
M.D., Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
As Senior Vice President and Chief Medical Officer of the American Society of Clinical Oncology, Dr. Schilsky is involved in professional and patient education, quality improvement, policy and advocacy, communications, clinical research and development of CancerLinQ, ASCO’s rapid learning system for oncology. Prior to joining ASCO, Dr. Schilsky was a faculty member at the University of Chicago from 1984-2012. He served as Director of the University of Chicago Cancer Research Center (1991-99), as Associate Dean for Clinical Research (1999-2007) and as Chief of the Section of Hematology-Oncology (2009-2012). He presently serves as a member of the Board of Directors of the Reagan-Udall Foundation for the FDA, of Friends of Cancer Research and of the National Coalition for Cancer Research, and as a member of the National Cancer Policy Forum of the National Academy of Medicine. Dr. Schilsky has served as a member of the Board of Directors of ASCO and of the Conquer Cancer Foundation of ASCO and as ASCO President 2008-2009.
M.D., CEO and founder, IncellDx
Dr. Patterson was an Associate Professor of Pathology and Infectious Diseases and Director of Virology at Stanford University. He received his MD at Northwestern University Feinberg School of Medicine followed by a residency in pathology, with an undergraduate in molecular biology from the University of Michigan, Ann Arbor. During the early stages of the AIDS epidemic, Dr. Patterson investigated cellular reservoirs of HIV-1 using molecular and in situ cell based technology patented in his laboratory and used today around the world. Dr. Patterson determined that enough HIV virus was present in infected individuals to account for the massive destruction of the immune system. This paradigm altering work was published in Science in 1993 and featured in Scientific American, Rolling Stone, and on the Discovery Channel. Dr. Patterson has authored over 100 manuscripts and book chapters focusing on single cell biology and diagnostics.
M.S.E.E, CEO, Cellworks
Committed to the delivery of Precision Medicine for cancer care, Yatin Mundkur leads Cellworks Group in transforming the treatment of cancer through personalized medicine. As CEO of Cellworks, Yatin Mundkur develops company strategy and commercialization of both its Precision Medicine and its Stratified Medicine businesses. Over the last 25 years, Yatin has launched businesses in medical diagnostics, technology and communications, delivering strong returns to investors consistently. As a Silicon Valley Venture capitalist, he focuses on early-stage Technology and Healthcare investments. He is also on the Boards of Prysm, mSupply, Virsec, Xambala, Yantra and zSpace. Prior to joining Artiman Ventures, Yatin Mundkur was Managing Director at TeleSoft Partners, where he led investments in over twenty companies, in the early stage semiconductor and software sectors. Formerly, he held executive and engineering roles in multiple technology companies.